Efficacy assessment of a novel endolysin PlyAZ3aT for the treatment of ceftriaxone-resistant pneumococcal meningitis in an infant rat model

Luca G. Valente1,2,3, Ngoc Dung Le1,3, Melissa Pitton2,3, Gabriele Chiffi1,3, Denis Grandgirard1, Stephan M. Jakob2, David R. Cameron2, Grégory Resch4, Yok-Al Que2, Stephen L. Leib1,*

1 Institute for Infectious Diseases, University of Bern, Bern, Switzerland, 2 Department of Intensive Care Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland, 3 Graduate School for Cellular and Biomedical Sciences, University of Bern, Bern, Switzerland, 4 Centre for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital, Lausanne, Switzerland

*stephen.leib@ifik.unibe.ch

Abstract

Background
Treatment failure in pneumococcal meningitis due to antibiotic resistance is an increasing clinical challenge and alternatives to antibiotics warrant investigation. Phage-derived endolysins efficiently kill gram-positive bacteria including multi-drug resistant strains, making them attractive therapeutic candidates. The current study assessed the therapeutic potential of the novel endolysin PlyAZ3aT in an infant rat model of ceftriaxone-resistant pneumococcal meningitis.

Methods
Efficacy of PlyAZ3aT was assessed in a randomized, blinded and controlled experimental study in infant Wistar rats. Meningitis was induced by intracisternal infection with 5 x 10^7 CFU/ml of a ceftriaxone-resistant clinical strain of S. pneumoniae, serotype 19A. Seventeen hours post infection (hpi), animals were randomized into 3 treatment groups and received either (i) placebo (phosphate buffered saline [PBS], n = 8), (ii) 50 mg/kg vancomycin (n = 10) or (iii) 400 mg/kg PlyAZ3aT (n = 8) via intraperitoneal injection. Treatments were repeated after 12 h. Survival at 42 hpi was the primary outcome; bacterial loads in cerebrospinal fluid (CSF) and blood were secondary outcomes. Additionally, pharmacokinetics of PlyAZ3aT in serum and CSF was assessed.

Results
PlyAZ3aT did not improve survival compared to PBS, while survival for vancomycin treated animals was 70% which is a significant improvement when compared to PBS or PlyAZ3aT (p<0.05 each). PlyAZ3aT was not able to reduce bacterial loads in the CSF, whereas Vancomycin sterilized the CSF and within 25 h.
Pharmacokinetic studies indicated that PlyAZ3aT did not cross the blood brain barrier (BBB). In support, PlyAZ3aT showed a peak concentration of 785 μg/ml in serum 2 h after intraperitoneal injection but could not be detected in CSF.

**Conclusion**

In experimental pneumococcal meningitis, PlyAZ3aT failed to cure the infection due to an inability to reach the CSF. Optimization of the galenic formulation e.g. using liposomes might enable crossing of the BBB and improve treatment efficacy.

**Introduction**

The emergence and the spread of antimicrobial resistance in the last decades are major threats to human health. Alternative treatment strategies targeting antibiotic-resistant bacteria are urgently needed. One such approach is the use of endolysins (or lysins). Lysins are bacteriophage-derived enzymes with peptidoglycan hydrolase activity and are thereby able to degrade the bacterial cell wall. Recent in vitro and in vivo results suggest that endolysins might be promising antimicrobial agents. First, they rapidly lyse bacterial cells including those that are multi-drug resistant [1–6]. Second, they act very specifically, killing only strains from closely related species and do not affect off-target commensal bacteria, which makes them less likely to disturb the physiologic microflora [1, 4, 7]. Third, the frequency of resistance emergence seems to be low [8, 9]. Finally, they appear safe; in 2 recent clinical trials, no detrimental effects were observed after topical [10] or intravenous [11] application in humans.

*Streptococcus pneumoniae* is an opportunistic human pathogen that can cause diseases like sinusitis, otitis media, pneumonia, septicemia, and meningitis. Meningitis due to pneumococci is associated with important morbidity and mortality. Despite the availability of appropriate antibiotic treatment, pneumococcal meningitis (PM) is associated with a high case-fatality rate of up to 37% in high-income countries [12, 13]. By the end of the 20th century, a concerning increase in antimicrobial resistance was recognized for *S. pneumoniae* [14]. This was mitigated by the implementation of the pneumococcal conjugate vaccines (PCV), which led to a concomitant decrease in the rate of invasive pneumococcal diseases (IPD) [15, 16] and overall antimicrobial resistance [17–19]. Yet, as high as 30% of infections caused by *S. pneumoniae* remain resistant to at least one antibiotic [20], and cephalosporin-resistance in PM represents an emerging threat [21]. Additionally, serotype redistribution caused by vaccine selection pressure has been observed [22–24], leading to the risk of the re-emergence and spread of non-vaccine serotypes that are resistant to antibiotics.

The efficacy of different pneumococcal endolysins (e.g. Cpl-1 and Pal) has been previously assessed in experimental in vivo models for pneumonia [25], endocarditis [26], bacteremia [4, 6], and otitis media [27]. In an animal model of PM, Cpl-1 reduced bacterial loads within the central nervous system (CNS) after a single intracisternal or intraperitoneal injection [28]. Overall, in principle endolysins seem attractive therapeutic candidates to treat pneumococcal infections.

So far, however, the translation of promising preclinical applications of endolysin into clinical trials has been strikingly slow. We adapted a well-established infant rat model of PM and evaluated the efficacy of a novel endolysin called PlyAZ3aT for the treatment of a ceftriaxone-resistant *S. pneumoniae* serotype 19A strain in a randomized, blinded, and controlled animal study. As PM affects in particular children under the age of 5 years, infant rats are especially
well suited to mimic pediatric bacterial meningitis, since they reflect the developmental stage of this specific population.

**Material and methods**

**Infecting bacterial strain**

A ceftriaxone-resistant (in accordance with CLSI guidelines, MIC $\geq 2 \mu$g/ml as determined by E-test, [Biomérieux, Nürtingen, Germany]) clinical isolate of *S. pneumoniae*, serotype 19A (identified as SPn28) was used. Bacteria were routinely grown overnight at 37˚C in brain heart infusion broth (BHI, BD, USA), adjusted to an optical density (OD$_{570}$) of 0.1, and then further diluted tenfold in fresh and pre-warmed BHI medium. The subculture was grown for 2 h to reach logarithmic growth phase. Colony forming units (CFU) were determined on Columbia sheep blood agar (CSBA) plates.

**Expression and purification of PlyAZ3a$^T$**

Endolysin was produced as previously described, with minor modification [29, 30]. Briefly, the gene coding for PlyAZ3a$^T$ was amplified from the genome of *Streptococcus tigurinus* strain AZ3a$^T$ [31] by PCR using specific primers (5′ - ATGAAGAAAAACGACTTATTCATCGACG–3′ and 5′ - ATTTAGTGGTAACAATTAGTCCATCAGGTAATACATC–3′), cloned into plasmid pIN-IIIA and transformed into *E. coli* DH5α. Expression was induced by addition of 2% (w/v) lactose. PlyAZ3a$^T$ binds strongly to diethylaminoethyl (DEAE). Therefore, crude extracts of PlyAZ3a$^T$ were purified by fast protein liquid chromatography (FPLC) with HiTrap DEAE FF columns (GE Healthcare Bio-Science AB, Uppsala, Sweden) followed by endotoxin removal to < 1 endotoxin units (EU)/mg (ToxinEraser™ Endotoxin Removal Kit, GenScript, Leiden, Netherlands) and dialysis against phosphate-buffer saline (PBS, pH 7.4) (Slide-A-Lyzer™ Dialysis Flasks, ThermoFisher, Reinach, Switzerland). Residual endotoxin concentration was determined by ToxinSensor™ Chromogenic LAL Endotoxin Assay Kit (GenScript, Leiden, Netherlands) and endolysin concentrations using Pierce™ BCA Protein Assay Kits (ThermoFisher, Reinach, Switzerland).

**Characterization of PlyAZ3a$^T$**

To assess similarities of PlyAZ3a$^T$ (GenBank: EMG32405.1) to the well-characterized pneumococcal endolysin Cpl-1 (GenBank: NP_044837.1) protein alignment was performed using BLASTp [32]. Killing efficacy of PlyAZ3a$^T$ was assessed on SPn28 and compared to vancomycin. SPn28 was grown to exponential phase and treated with either PlyAZ3a$^T$ (1 µg/ml, 100 µg/ml or 200 µg/ml), vancomycin (1 µg/ml) or PBS. Bacteria were incubated statically at 37˚C with 5% CO$_2$ and CFU were quantified before treatment, and 1, 2, 4 and 6 h after treatment. Prior to quantification on agar plates, 10 µl of PlyAZ3a$^T$-treated samples was added to 90 µl of NaCl 0.85% containing 10% w/v choline (Sigma Aldrich, Buchs, Switzerland) in order to block further activity of the enzyme. Six biological replicates were performed for each condition. The effect of temperature and pH on enzymatic activity of PlyAZ3a$^T$ was evaluated as previously described by Son et al. [33].

**Assessment of toxicity and inflammation in primary astroglial cell culture**

The use of animal for cell culture experiments was approved by the animal care and experimentation committee of the canton of Bern, Switzerland (license no. BE 6/20). Primary astroglial cells were isolated and processed from 2-day old infant Wistar rats (central animal facility of the Medical Faculty of the University of Bern, Switzerland) as previously described [34, 35].
with minor adaptations. After 11 days of cultivation, cells were seeded in 24-well plates (~250'000 cells/well) precoated with poly-L-ornithine (0.01 mg/ml in PBS, Buchs, Sigma-Aldrich). Three days later, astroglial cells were exposed for 24 h to (i) sterile PBS (pH 7.4), (ii) 10 μg/ml lipopolysaccharide (LPS) from E. coli 026:B6 (Sigma Aldrich, Switzerland), (iii) 100 μg/ml PlyAZ3aT or (iv) 2% Triton X-100 (Merck, Darmstadt, Germany). Production of NO$_2^-$ was assessed in the supernatant of cell cultures as previously described [34, 35]. Viability of cells was assessed using an XTT assay, according to manufacturer’s instruction (Cell Proliferation Kit II, Sigma Aldrich, Buchs, Switzerland). The experiment was performed twice and in biological replicates of 18 for every condition.

Changes in inducible nitric oxide synthase (iNOS) expression were also assessed by immunofluorescence. Cells were fixed with 4% paraformaldehyde (PFA, Merck, Switzerland) diluted in PBS for 10 min at room temperature, followed by three washing cycles with sterile PBS. Permeabilization was done with 0.1% Triton X-100 (TX-100, Merck, Zug, Switzerland) for 5 min, followed by a 1 h blocking with blocking buffer (0.01% TX-100 + 2% bovine serum albumin, dissolved in PBS). Primary antibodies consisted of anti-GFAP mouse antibodies for astrocytes (dilution 1:1000; ThermoFisher, Reinach, Switzerland) and anti-NCOA3 rabbit antibodies for iNOS (dilution 1:500; Amsbio, Abingdon, UK). Secondary antibodies were goat anti-mouse Cy3 for astrocytes (dilution 1:500; ABCAM, Switzerland) and donkey anti-mouse Cy3 for iNOS (dilution 1:500; ThermoFisher, Switzerland), dissolved in blocking buffer. Secondary antibodies were added after overnight incubation of the primary antibodies at 4˚C and three washing cycles with PBS and incubated for additional 2 h at room temperature. 4',6'-diamidino-2-phenylindole (DAPI, ThermoFisher, Reinach, Switzerland) was used to visualize cell nuclei. Images were generated using fluorescence microscopy (OLYMPUS CKX53, Olympus LS, Germany).

Infant rat model of pneumococcal meningitis

All animal experiments were approved by the animal care and experimentation committee of the canton of Bern, Switzerland (license no. BE 5/20). Animals had access to water and food ad libitum and were kept in rooms with controlled temperature (22 ± 2˚C) and natural light.

A well-established infant rat model for PM was used as previously described [34–38] and adapted to use the serotype 19A clinical isolate SPn28. SPn28 was passaged 3 times in infant rats before further investigations were performed.

Mixed-sex Wistar rats (outbred, 11-day old) and their dams were purchased from Charles River Laboratories (Sulzfeld, Germany). Bacteria in logarithmic growth phase were used as inoculum and were washed twice by centrifugation (3100xg, 10 min at 4˚C) and resuspended in ice cold sterile saline (NaCl 0.85%), followed by dilution to reach the desired OD$_{570}$ of 0.15.

Bacterial inoculation (10 μl containing 3.9 ± 0.25 x 10$^7$ CFU/ml SPn28) was performed by injection into the cisterna magna. This amount of inoculum was chosen according to the results of LD$_{90}$ experiments (S1 Fig). CSF sampling was performed by puncture of the cisterna magna using a 30-gauge needle and blood sampling by puncturing the facial vein with a 20-gauge needle and collection of 1 drop (approximately 50 μl). Clinical signs of meningitis arose at 17 hours post infection (hpi), and this correlated with quantitative analysis of bacterial titers in the CSF. This timepoint was chosen for the first treatment dose. Clinical scoring and weighing were performed at 17, 24 and 42 hpi as described previously [36]. Briefly, clinical score was determined as follows: 5 = healthy with normal behavior; 4 = turns upright within 5 s, weight loss and/or appearance of fur; 3 = turns upright within 30 s; 2 = inability to turn upright; 1 = marked diminished motor activity, coma. Animals were sacrificed upon reaching a score of ≤ 2 to meet ethical requirements. At 42 hpi all remaining animals were sacrificed by
intraperitoneal (i.p.) injection of pentobarbital (Esconarkon®, 150 mg/kg, Streuli Pharma AG, Switzerland) followed by perfusion with 4% PFA. Brains were collected for histomorphometric analysis of cortical damage and hippocampal apoptosis, which was performed as previously described [35, 39, 40].

Pharmacokinetic study. In order to assess pharmacokinetic properties of PlyAZ3a₅, infected animals were treated with a single i.p. injection of either 100 mg/kg or 400 mg/kg b.w. PlyAZ3a₅ at 17 hpi. Animals were separated in 2 groups (n = 16 per group) with different sample withdrawal times, in order to avoid excessive sampling frequency from the same animals. CSF and blood samples were taken at 15 min, 4 h and 12 h for the first group and at 2 h, 6 h and 12 h for the second group. If animals reached a clinical score ≤ 2, samples were taken after sacrifice and included into the analysis. Blood was collected in serum Microvettes® 200 Z (Sarstedt, Nümbrecht, Germany).

Treatment study. The procedure for the randomized, blinded and controlled study of PM was as follows. CSF sampling was performed at 17 hpi to confirm meningitis and all animals were randomly allocated into 3 groups using GraphPad (https://www.graphpad.com/quickcalcsc/randomize1.cfm). Treatment groups were (i) placebo (sterile PBS), (ii) PlyAZ3a₅ 400 mg/kg b.w. and (iii) Vancomycin 50 mg/kg b.w. (Vancocin, in saline, Teva, Petach Tikwa, Israel). Treatments were applied twice daily (12-hour time interval) through an i.p. injection. All persons involved in animal treatment were blinded regarding treatment groups until the end of the experiment. The primary endpoint was survival at 42 hpi. Secondary endpoints were (i) CFU in CSF and blood at 6 and 25 h post treatment and (ii) extent of cortical necrosis and hippocampal apoptosis in histopathological analysis.

The volume of CSF recovered from each animal during sampling was restricted and ranged from 5 to 15 μl. This resulted into a limit of detection for CFU quantification of 1 x 10³ CFU/ml.

Animals displaying a clinical score of ≤ 2 prior to the time of randomization were sacrificed immediately and excluded from the analysis. Similarly, animals without established meningitis at randomization, defined by bacterial titers in CSF <1 x 10⁴ CFU/ml at 17 hpi, were excluded from the analysis.

Quantification of PlyAZ3a₅ in CSF and blood samples

The amount of PlyAZ3a₅ in CSF and serum samples was assessed by quantitative near infrared Western Blot (NIR-WB). Proteins in CSF or serum were separated using 10% SDS-polyacrylamide gels. Western blotting and immunostaining were performed with WesternBrightTM MCF and MCF-IR kit (Advansta, San Jose, USA) according to manufacturer’s instructions. PlyAZ3a₅ was detected as a 41 kD band, by using a primary antibody (custom-produced PlyAZ3a₅-specific polyclonal rabbit antibody, David’s Biotechnology, Regensburg, Germany). Fluorescence was measured using a Fusion FX6 EDGE System (Vilber Lourmat, Collégien, France) with an exposure time of 2 min. Quantification of PlyAZ3a₅ was performed by comparison to a standard curve of PlyAZ3a₅ ranging from 2–0.02 μg using FIJI (version 1.8). The limit of detection was 10 μg/ml.

Analysis of cytokines in cell culture supernatant

Inflammatory cytokines known to be upregulated in PM (IL-1β, IL-6 and TNF-α) were measured in cell supernatants and CSF samples using a magnetic multiplex assay (Rat Magnetic Luminex® Assay, R&D Systems, Bio-Techne) on a Bio-Plex 200 station (Bio-Rad Laboratory) as reported previously [35, 41].
Plate lysis assay for endolysin resistance testing

Plate lysis assay was performed as described previously [42–44] to assess resistance and activity against various pneumococcal serotypes. Bacteria recovered from animals was grown to exponential phase and plated on a CSBA to produce uniform bacterial lawns. PlyAZ3aT (0.5 μg) was spotted onto the plate and incubated overnight. Bacteria were classified as susceptible to PlyAZ3aT if a clear lysis zone was observed.

Statistical analysis

Statistical analyses were performed using GraphPad Prism® (San Diego, USA). Differences in survival were calculated using log-rank tests. Differences between means of non-normally distributed groups (cytokines, cortical necrosis, hippocampal apoptosis) were assessed using Kruskal-Wallis test with Dunn’s multiple comparison. Differences in CFU reduction in CSF and blood of animals were calculated using Fisher’s exact test. A p value < 0.05 was considered statistically significant.

Results

PlyAZ3aT lyzes ceftriaxone-resistant S. pneumoniae in vitro

PlyAZ3aT is a bacteriophage-derived endolysin found within the genome of S. tigrinus strain AZ3aT (Accession number GCA_000344275.1). Alignment of the amino acid sequence of PlyAZ3aT and Cpl-1 (up to now the most extensively characterized pneumococcal endolysin) displayed 80% similarity for the putative catalytic domain and 47% similarity for the putative cell-wall binding domain (Fig 1A), suggesting PlyAZ3aT might be active against S. pneumoniae. Indeed, PlyAZ3aT exhibit a broad-spectrum lytic activity against S. pneumoniae, lysing 18 distinct serotypes including both PCV 13 (3, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) and non-PCV 13 serotypes (11A, 15A, 17F, 20, 22F, 23B and 35B), as tested by plate lysis assay. No resistance to the endolysin activity could be detected among the tested isolates (n = 18). PlyAZ3aT lysed S. pneumoniae efficiently (>50% of maximal efficacy) at temperatures ranging from 25–42˚C (Fig 1B) and for pH ranging from 5–7. Optimal activity occurred at pH 6, while pH < 9 completely inactivated the enzyme (Fig 1B). In time-kill curve assays, PlyAZ3aT showed a dose-dependent killing of the ceftriaxone-resistant strain SPn28. The bacteria were not eradicated even after 6 h of exposure to the lysin at the highest concentration of 200 μg/ml (Fig 1C). In contrast, vancomycin displayed a bactericidal effect and reduced counts below the detection limit within the same time period (Fig 1C).

PlyAZ3aT failed to control ceftriaxone-resistant pneumococcal meningitis

In primary astroglial cell cultures, no direct toxicity of PlyAZ3aT was observed (S2A and S2B Fig). Exposure led to a minimal inflammatory response when compared to the inflammatory control LPS as inferred by NO2− and cytokine levels (S2C and S2D Fig), suggesting the protein was safe for animal administration. Overall, 38 infant Wistar rats were included in the treatment study, which was performed in 2 independent experiments. At the time of randomization (17 hpi), 8 animals had to be excluded due to a clinical score ≤ 2. The 30 remaining animals were randomly allocated to receive either (i) placebo (n = 8), (ii) PlyAZ3aT (n = 11) or (iii) vancomycin (n = 11) (S3 Fig). Post hoc additional 4 animals not having established meningitis (<1 x 10⁴ CFU/ml in the CSF at 17 hpi) had to be excluded (n = 3 for PlyAZ3aT, n = 1 for vancomycin).

PlyAZ3aT was not superior to placebo in improving survival of animals with PM (p > 0.05, Fig 2A). In contrast, the standard-of-care antibiotic vancomycin significantly improved
survival with a rate of 70% survival (p = 0.02 versus PBS and PlyAZ3a\textsuperscript{T}, Fig 2A). PlyAZ3a\textsuperscript{T} did not significantly reduce bacterial loads in the CSF and blood over the course of infection when compared to placebo (p > 0.05, Table 1). On the opposite, vancomycin-treated animals displayed a consistent reduction of bacterial loads in both CSF and blood within the first 6 h after start of therapy (CSF p = 0.0182 and blood p = 0.021 compared to placebo, Table 1). In surviving animals under vancomycin treatment, the infection was cleared within 25 h of treatment (S4 Fig). The kinetics of bacteria in blood of PlyAZ3a\textsuperscript{T} and placebo treated animals are displayed in S4 Fig. Finally, the extent of cortical necrosis and the number of apoptotic cells of the subgranular zone of the dentate gyrus were similar among all groups (p > 0.05 for all comparisons) (S5A and S5B Fig).

Reduced bioavailability of PlyAZ3a\textsuperscript{T} in CSF

We further investigated whether the lack of efficacy of PlyAZ3a\textsuperscript{T} in the experimental meningitis model was associated either with the emergence of endolysin resistance or with an altered pharmacokinetic profile. First, bacteria recovered from PlyAZ3a\textsuperscript{T} treated animals (60 colonies in total) were tested for resistance and all remained susceptible to lysis. Second, PlyAZ3a\textsuperscript{T} was quantified from the serum and CSF of infected animals receiving a single dose of either 100 mg/kg or 400 mg/kg b.w. PlyAZ3a\textsuperscript{T}. PlyAZ3a\textsuperscript{T} was detected in the serum (Fig 2B), peaked after 2 h of intraperitoneal administration (268 μg/ml for 100 mg/kg group and 785 μg/ml for 400 mg/kg group), and was detected up to 12 h in the 400 mg/kg BW group, albeit at low levels (Fig 2C). In contrast, PlyAZ3a\textsuperscript{T} was not detected in the CSF of any of the animals tested, at any time point (Fig 2B, limit of detection 10 μg/ml).
Despite the introduction of the pneumococcal conjugate vaccine 13 (PCV13), *S. pneumoniae* serotype 19A remains a major causative of invasive pneumococcal disease and meningitis [22, 45]. In addition, serotype 19A is among the major serotypes associated with penicillin or ceftriaxone resistance.

**Fig 2. Treatment of ceftriaxone-resistant pneumococcal meningitis using PlyAZ3aT.** (A) Kaplan-Meier survival curve of Wistar rats treated with either PBS (n = 8), 400 mg/kg PlyAZ3aT (n = 8) or 50 mg/kg Vancomycin (n = 10). Treatment was applied intraperitoneally twice daily. Significance was determined by log-rank test. (B) Anti-PlyAZ3aT near-infrared western blots of serum or CSF samples recovered from one animal treated with a single intraperitoneal injection at 15 min and 4 h after injection. (C) Pharmacokinetic assessment of PlyAZ3aT in serum of Wistar pups (n = 16 per group) after one single intraperitoneal injection. Limit of detection 10 μg/ml. Data are presented as mean ± standard deviation.

https://doi.org/10.1371/journal.pone.0266928.g002

**Discussion**

Despite the introduction of the pneumococcal conjugate vaccine 13 (PCV13), *S. pneumoniae* serotype 19A remains a major causative of invasive pneumococcal disease and meningitis [22, 45]. In addition, serotype 19A is among the major serotypes associated with penicillin or ceftriaxone resistance.

**Table 1. Comparison of the decrease of CFU in CSF and blood between treatment groups within the first 6 h after treatment.** (A) Comparison of CFU reduction in CSF and (B) in blood. Statistical significance was determined using Fisher’s exact test. Animals displaying bacterial loads below the limit of detection throughout the experiment or missing follow-up sampling were excluded from the analysis.

|                | CSF Decrease | No Decrease | Comparison to PBS |
|----------------|--------------|-------------|-------------------|
| PBS            | 1            | 3           |                   |
| PlyAZ3aT       | 2            | 4           | *p > 0.05*        |
| Vancomycin     | 8            | 0           | *p = 0.0182*      |

B) Numbers of animals displaying decrease of CFU in blood

|                | CSF Decrease | No Decrease | Comparison to PBS |
|----------------|--------------|-------------|-------------------|
| PBS            | 2            | 5           |                   |
| PlyAZ3aT       | 6            | 1           | *p > 0.05*        |
| Vancomycin     | 6            | 0           | *p = 0.021*       |

https://doi.org/10.1371/journal.pone.0266928.t001
cephalosporin resistance [22]. Having a wider range of treatment alternatives to combat ceftriaxone-resistant pneumococci is of necessity. Herein, we investigated whether a novel phage lysine recently isolated from *S. tigurinus* strain AZ3αT [31] would be effective for the treatment of *S. pneumoniae* serotype 19A either in vitro or in vivo, in an experimental bacterial meningitis model in infant rats. In vitro, PlyAZ3αT showed a broad host-range and was able to lyse all tested *S. pneumoniae* serotypes independently from their antibiotic resistance profile. PlyAZ3αT induced a quick and dose-dependent reduction of bacterial loads of the ceftriaxone-resistant serotype 19A. Furthermore, the endolysin was safe and did not induce any evident direct toxic effect in astroglial cell cultures. Only minor inflammatory reactions were observed, mostly related to residual endotoxin activity.

*In vivo*, PlyAZ3αT failed to improve survival, to reduce bacterial numbers in the CSF or to prevent systemic spreading of the infection in blood compared to placebo. On the other hand, vancomycin significantly increased survival to 70%, which is in accordance with survival rates observed in previous studies when using standard of care treatment in this animal model [34, 35, 38]. PlyAZ3αT showed an important pharmacokinetic limitation, as endolysin could not be detected in CSF of endolysin treated animals most likely as a result of its inability to cross the BBB or the low stability of the protein in this environment. A possible solution to bypass this limitation is the use of direct intracisternal application, which is not devoid of problems either, as shown in a previous investigation assessing the pneumococcal endolysin Cpl-1 in the similar experimental setting [28]. There, Cpl-1 exhibited a short half-life time of ~16 min after direct intracisternal application, leading to bacterial regrowth within 4 h and prompting the necessity of repeated intracisternal injections, which on their part where harmful [28]. An intracisternal-sustained release might help to optimize the pharmacokinetic profile. In bacterial meningitis, such an opportunity might be found when an external ventricular drain (EVD) is available, allowing for a continuous delivery of endolysin directly to the CNS thereby circumventing the BBB. Alternatively, innovative galenic formulations (e.g. using liposomes) might improve the ability of the endolysin to cross the BBB allowing for an intravenous administration.

Taken together, our results highlighted the pitfalls and drawbacks of the application of PlyAZ3αT, and possibly endolysins in general, in bacterial meningitis. Despite a well described break down of the BBB in bacterial meningitis the BBB seems to remain largely impermeable to such phage proteins. As such, endolysins might be more suitable for the treatment of other bacterial infections as it was shown for Cpl-1, such as bacteremia [4, 6], pneumonia [25] or endocarditis [26] where the endolysin can efficiently and readily reach the infection site.

**Supporting information**

**S1 Fig. Adaptation of a ceftriaxone-resistant pneumococcal strain (serotype 19A) to the infant rat model of meningitis.** Kaplan-Meier survival curves for LD₉₀ finding of the new strain (A) before and (B) after 3 passages in infant rats. 10 μl of the corresponding inoculum were injected.

(TIF)

**S2 Fig. PlyAZ3αT induces a minimal inflammatory reaction with no direct toxicity in confluent primary astroglial cell cultures.** Cells were exposed for 24 h to either PBS (negative control), LPS (positive control), PlyAZ3αT or TritonX (membrane disrupting agent). (A) Immunohistological staining in astroglial cell cultures, iNOS is stained in green (anti-iNOS), astroglia is stained in red (anti-GFAP) and cell nuclei in blue (4',6-Diamidin-2-phenylindole, DAPI). (B) Viability of cells was confirmed by using an XTT-assay (the mean of PBS treated cells is defined as 100%). (C) Production of NO₂⁻ measured as an index for nitric oxide (NO) release. (D) Levels of IL-1β, TNF-α and IL-6. Data are presented as mean ± standard deviation.
Statistical differences between groups were assessed using Kruskal-Wallis test with Dunn’s multiple comparisons; *p<0.05, **** p<0.0001.

(TIF)

S3 Fig. Flowchart of the randomized, blinded and controlled experimental study.
(TIF)

S4 Fig. Tracked course of bacterial loads in CSF (black) and blood (purple) in each single animal. Tracking of bacterial loads displayed for the first six hours or until the end of the experiment (25 hours post treatment). Dots connected with lines represent repeated sampling in one single animal. CFU, colony forming unit.
(TIF)

S5 Fig. Histopathological assessment of cerebral complications after acute pneumococcal meningitis. (A) Comparison in percentage of necrotizing cortex between groups and (B) number of apoptotic cells in the hippocampus. Animals reaching the end of the 42 hours trial are represented by closed circles and succumbed prematurely to the infection by crosses. Statistical significance was assessed using Kruskal-Wallis test with Dunn’s multiple comparisons, ns, not significant.
(TIF)

S1 Raw images. Raw images of the western blots displayed in Fig 2B. The red rectangle corresponds to the section displayed in Fig 2B. Lanes not included in the final figure are marked with an “X”.
(PDF)

S1 Table. Overview of the raw data of CFU detected in CSF. Bacterial loads are displayed as \( \text{Log}_{10} \) (CFU). Hpt, hours post treatment. N/A, not available due to failed sampling. Limit of detection is 3 \( \text{Log}_{10} \).
(TIFF)

S2 Table. Overview of the raw data of CFU detected in blood. Bacterial loads are displayed as \( \text{Log}_{10} \) (CFU). Hpt, hours post treatment. N/A, not available due to failed sampling. Limit of detection is 3 \( \text{Log}_{10} \).
(TIFF)

S3 Table. Spreadsheet containing raw data to Figs 1 and 2.
(XLSX)

S4 Table. Spreadsheet containing raw data to supplemental figures.
(XLSX)

**Acknowledgments**

We acknowledge the outstanding technical assistance of Maria Erhardt, Sandra Nansoz, Franziska Simon, Romano Josi and Jonathan Save. We thank Carlo Casanova and Markus Hilty from the Swiss National Center for Pneumococci (https://www.ifik.unibe.ch/services/pneumococcal_center/index_eng.html) for generously providing us a ceftriaxone-resistant \( S. \) pneumoniae (serotype 19A). We thank Andrea Zbinden for having kindly provided us with the \( S. \) tigurinus strain AZ3a\(^T\).
Author Contributions

Conceptualization: Luca G. Valente, Denis Grandgirard, Stephan M. Jakob, David R. Cameron, Yok-Ai Que, Stephen L. Leib.

Formal analysis: Luca G. Valente.

Funding acquisition: Yok-Ai Que, Stephen L. Leib.

Investigation: Luca G. Valente, Ngoc Dung Le, Melissa Pitton, Gabriele Chiffi, Denis Grandgirard, Grégory Resch.

Methodology: Luca G. Valente, Ngoc Dung Le, David R. Cameron.

Project administration: Luca G. Valente.

Supervision: Yok-Ai Que, Stephen L. Leib.

Writing – original draft: Luca G. Valente.

Writing – review & editing: Luca G. Valente, Ngoc Dung Le, Melissa Pitton, Gabriele Chiffi, Denis Grandgirard, Stephan M. Jakob, David R. Cameron, Grégory Resch, Yok-Ai Que, Stephen L. Leib.

References

1. Loeffler JM, Nelson D, Fischetti VA. Rapid killing of *Streptococcus pneumoniae* with a bacteriophage cell wall hydrolase. Science (New York, NY). 2001 Dec 7; 294(5549):2170–2. https://doi.org/10.1126/science.1066895 PMID: 11739958

2. Obeso JM, Martínez B, Rodríguez A, García P. Lytic activity of the recombinant staphylococcal bacteriophage PhiH5 endolysin active against *Staphylococcus aureus* in milk. International journal of food microbiology. 2008 Dec 10; 128(2):212–8. https://doi.org/10.1016/j.ijfoodmicro.2008.08.010 PMID: 18809219

3. Díez-Martínez R, De Paz HD, García-Fernández E, Bustamante N, Euler CW, Fischetti VA, et al. A novel chimeric phage lysin with high in vitro and in vivo bactericidal activity against *Streptococcus pneumoniae*. The Journal of antimicrobial chemotherapy. 2015 Nov 12; 70(6):1763–73. https://doi.org/10.1093/jac/dkv038 PMID: 25733585

4. Loeffler JM, Djurkovic S, Fischetti VA. Phage lytic enzyme Cpl-1 as a novel antimicrobial for pneumococcal bacteremia. Infection and immunity. 2003 Nov; 71(11):6199–204. https://doi.org/10.1128/IAI.71.11.6199-6204.2003 PMID: 14573637

5. Rashel M, Uchiyama J, Ujihara T, Uehara Y, Kuramoto S, Sugihara S, et al. Efficient elimination of multidrug-resistant *Staphylococcus aureus* by cloned lysin derived from bacteriophage phi MR11. The Journal of infectious diseases. 2007; 196(8):1237–47. https://doi.org/10.1086/521305 PMID: 17955443

6. Jado I, López R, García E, Fenoll A, Casal J, García P, et al. Phage lytic enzymes as therapy for antibiotic-resistant *Streptococcus pneumoniae* in a murine sepsis model. Journal of Antimicrobial Chemotherapy. 2003 Dec; 52(6):967–73.

7. Nelson D, Loomis L, Fischetti VA. Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme. Proceedings of the National Academy of Sciences of the United States of America. 2001 Mar 27; 98(7):4107–12. https://doi.org/10.1073/pnas.061038398 PMID: 11259652

8. Rodríguez-Rubio L, Martínez B, Rodríguez A, Donovan DM, Gótz F, García P. The phage lytic proteins from the *Staphylococcus aureus* bacteriophage vB_SauS-phiLAB8 display multiple active catalytic domains and do not trigger staphylococcal resistance. PloS one. 2013 May 28; 8(5).

9. Totté JEE, van Doorn MB, Pasmans SGM. Successful Treatment of Chronic *Staphylococcus aureus*-Related Dermatoses with the Topical Endolysin Staphefekt SA.100: A Report of 3 Cases. Case reports in dermatology. 2017 May 22; 9(2):19–25. https://doi.org/10.1159/000473872 PMID: 28611631

10. de Wit J, Totté JEE, van Mierlo MMF, van Veldhuizen J, van Doorn MBA, Schuren FHJ, et al. Endolysin treatment against *Staphylococcus aureus* in adults with atopic dermatitis: A randomized controlled trial. The Journal of allergy and clinical immunology. 2019 Sep 1; 144(3):860–3. https://doi.org/10.1016/j.jaci.2019.05.026 PMID: 31145938
11. Jun SY, Jang IJ, Yoon S, Jang K, Yu KS, Cho JY, et al. Pharmacokinetics and Tolerance of the Phage Endolysin-Based Candidate Drug SAL200 after a Single Intravenous Administration among Healthy Volunteers. Antimicrobial agents and chemotherapy. 2017 Jun 1; 61(6). https://doi.org/10.1128/AAC.02629-16 PMID: 28348152

12. van de Beek D, de Gans J, Spanjaard L, Weisfelt M, Reitsma JB, Vermeulen M. Clinical features and prognostic factors in adults with bacterial meningitis. The New England journal of medicine. 2004 Oct 28; 351(18):1849–59. https://doi.org/10.1056/NEJMoa040845 PMID: 15059818

13. Van De Beek D, Brouwer M, Hasbun R, Koedel U, Whitney CG, Wijdicks E. Community-acquired bacterial meningitis. Nature reviews Disease primers. 2016 Nov 3; 2.

14. Liñares J, Ardanuy C, Pallares R, Fenoll A. Changes in antimicrobial resistance, serotypes and genotypes in Streptococcus pneumoniae over a 30-year period. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2010; 16 (5):402–10.

15. Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett NM, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. The Lancet Infectious diseases. 2015 Mar 1; 15(3):301–9. https://doi.org/10.1016/S1473-3099(14)71081-3 PMID: 25656600

16. Van de Beek D, de Gans J, Spanjaard L, Weisfelt M, Reitsma JB, Vermeulen M. Clinical features and prognostic factors in adults with bacterial meningitis. The New England journal of medicine. 2004 Oct 28; 351(18):1849–59. https://doi.org/10.1056/NEJMoa040845 PMID: 15059818

17. Olarte L, Barson WJ, Barson RM, Lin PL, Romero JR, Tan TQ, et al. Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Pneumococcal Meningitis in US Children. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2015 Sep 1; 61(5):767–75. https://doi.org/10.1093/cid/civ368 PMID: 25972022

18. Hampton LM, Farley MM, Schaffner W, Thomas A, Reingold A, Harrison LH, et al. Prevention of antibiotic-non-susceptible Streptococcus pneumoniae with conjugate vaccines. The Journal of infectious diseases. 2012 Feb 1; 205(3):401–11. https://doi.org/10.1093/infdis/jir755 PMID: 22158567

19. Tomczyk S, Lynfield R, Schaffner W, Reingold A, Miller L, Petit S, et al. Prevention of Antibiotic-Non-susceptible Invasive Pneumococcal Disease With the 13-Valent Pneumococcal Conjugate Vaccine. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2016 May 1; 62(9):1119–25. https://doi.org/10.1093/cid/cow067 PMID: 26908787

20. Prevention C for DC and. Streptococcus pneumoniae Report: Antibiotic Resistance Threats in the United States, 2019 [Internet]. 2019 [cited 2021 Nov 16]. https://www.cdc.gov/drugresistance/pdf/ threats-report/strep-pneumoniae-508.pdf

21. Aiba H, Shoji K, Shinjo D, Ishiguro A, Miyar I. Third-generation cephalosporin-resistant pneumococcal meningitis in children. Pediatrics international: official journal of the Japan Pediatric Society. 2021 Sep 1; 63(9):1135–3. https://doi.org/10.1111/ped.14569 PMID: 34176189

22. Kaplan SL, Barson WJ, Lin PL, Romero JR, Bradley JS, Tan TQ, et al. Invasive Pneumococcal Disease in Children's Hospitals: 2014–2017. Pediatrics. 2019; 144(3). https://doi.org/10.1542/peds.2019-0567 PMID: 31420369

23. Richter SS, Diekema DJ, Heilmann KP, Dohrn CL, Riahi F, Doern GV. Changes in pneumococcal serotypes and antimicrobial resistance after introduction of the 13-valent conjugate vaccine in the United States. Antimicrobial agents and chemotherapy. 2014 Nov 1; 58(11):6484–9. https://doi.org/10.1128/AAC.03344-14 PMID: 25136018

24. Meichtry J, Born R, Kükker M, Zwahlen M, Albrich WC, Brugger SD, et al. Serotype epidemiology of invasive pneumococcal disease in Swiss adults: a nationwide population-based study. Vaccine. 2014 Sep 8; 32(40):5185–91. https://doi.org/10.1016/j.vaccine.2014.07.060 PMID: 25077419

25. Doehn JM, Fischer K, Repp K, Gubtler B, Tschernig T, Hocke AC, et al. Delivery of the endolysin Cpl-1 by inhalation rescues mice with fatal pneumococcal pneumonia. The Journal of antimicrobial chemotherapy. 2013 Sep 1; 68(9):2111–7. https://doi.org/10.1093/jac/dkt131 PMID: 23633685

26. Entenza JM, Loeffler JM, Grandgirard D, Fischetti VA, Moreillon P. Therapeutic effects of bacterial- phage Cpl-1 lysin against Streptococcus pneumoniae endocarditis in rats. Antimicrobial agents and chemotherapy. 2005 Nov; 49(11):4789–92. https://doi.org/10.1128/AAC.49.11.4789-4792.2005 PMID: 16251333

27. McCullers JA, Karlström Å, Iverson AR, Loeffler JM, Fischetti VA. Novel strategy to prevent otitis media caused by colonizing Streptococcus pneumoniae. PLoS pathogens. 2007 Mar; 3(3). https://doi.org/10.1371/journal.ppat.0030028 PMID: 17381239

28. Grandgirard D, Loeffler JM, Fischetti VA, Leib SL. Phage lytic enzyme Cpl-1 for antibacterial therapy in experimental pneumococcal meningitis. The Journal of infectious diseases. 2008 Jun 1; 197(11):1519–22. https://doi.org/10.1086/587942 PMID: 18471063
29. Resch G, Moreillon P, Fischetti VA. A stable phage lysin (Cpl-1) dimer with increased antipneumococcal activity and decreased plasma clearance. International journal of antimicrobial agents. 2011 Dec; 38 (6):516–21. https://doi.org/10.1016/j.ijantimicag.2011.08.009 PMID: 21982146

30. Loeffler JM, Fischetti VA. Synergistic lethal effect of a combination of phage lytic enzymes with different activities on penicillin-sensitive and -resistant *Streptococcus pneumoniae* strains. Antimicrobial agents and chemotherapy. 2003 Jan 1; 47(1):375–7. https://doi.org/10.1128/AAC.47.1.375-377.2003 PMID: 12499217

31. Zbinden A, Mueller NJ, Tarr PE, Sproer C, Keller PM, Bloemberg GV. *Streptococcus tigurinus* sp. nov., isolated from blood of patients with endocarditis, meningitis and spondylodiscitis. International journal of systematic and evolutionary microbiology. 2012; 62(Pt 12):2941–5. https://doi.org/10.1099/ijs.0.038299-0 PMID: 22357776

32. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. Journal of molecular biology. 1990; 215(3):403–10. https://doi.org/10.1016/S0022-2836(05)80360-2 PMID: 2231712

33. Son B, Yun J, Lim JA, Shin H, Heu S, Ryu S. Characterization of LysB4, an endolysin from the *Bacillus cereus*-infesting bacteriophage B4. BMC microbiology. 2012; 12. https://doi.org/10.1186/1471-2180-12-33 PMID: 22416675

34. Muri L, Perny M, Zemp J, Grandgirard D, Leib SL. Combining Ceftriaxone with Doxycycline and Daptomycin Reduces Mortality, Neuroinflammation, Brain Damage, and Hearing Loss in Infant Rat Pneumococcal Meningitis. Antimicrobial agents and chemotherapy. 2019; 63(7).

35. Muri L, Le ND, Zemp J, Grandgirard D, Leib SL. Metformin mediates neuroprotection and attenuates hearing loss in experimental pneumococcal meningitis. Journal of neuroinflammation. 2019 Jul 27; 16 (1). https://doi.org/10.1186/s12974-019-1549-6 PMID: 31351490

36. Leib SL, Leppert D, Clements J, Tauber MG. Matrix metalloproteinases contribute to brain damage in experimental pneumococcal meningitis. Infection and immunity. 2000 Feb; 68(2):615–20. https://doi.org/10.1128/IAI.68.2.615-620.2000 PMID: 10639424

37. Grandgirard D, Burri M, Agyeman P, Leib SL. Adjunctive daptomycin attenuates brain damage and hearing loss more efficiently than rifampin in infant rat pneumococcal meningitis. Antimicrobial agents and chemotherapy. 2012 Aug; 56(8):4289–95. https://doi.org/10.1128/AAC.00674-12 PMID: 22644021

38. Muri L, Grandgirard D, Buri M, Perny M, Leib SL. Combined effect of non-bacteriolytic antibiotic and inhibition of matrix metalloproteinases prevents brain injury and preserves learning, memory and hearing function in experimental paediatric pneumococcal meningitis. Journal of neuroinflammation. 2018 Aug 21; 15(1). https://doi.org/10.1186/s12974-018-1272-8 PMID: 30131074

39. Grandgirard D, Steiner O, Tauber MG, Leib SL. An infant mouse model of brain damage in pneumococcal meningitis. Acta neuropathologica. 2007 Dec; 114(6):609–17. https://doi.org/10.1007/s00401-007-0304-8 PMID: 17938941

40. Liechti FD, Grandgirard D, Leppert D, Leib SL. Matrix metalloproteinase inhibition lowers mortality and brain injury in experimental pneumococcal meningitis. Infection and immunity. 2014; 82(4):1710–8. https://doi.org/10.1128/IAI.00073-14 PMID: 24491581

41. Le ND, Muri L, Grandgirard D, Kuhle J, Leppert D, Leib SL. Evaluation of neurofilament light chain in the cerebrospinal fluid and blood as a biomarker for neuronal damage in experimental pneumococcal meningitis. Journal of neuroinflammation. 2020 Oct 7; 17(1). https://doi.org/10.1186/s12974-020-01966-3 PMID: 33028339

42. Ugorcakova J, Medzova L, Solteszova B, Bukovska G. Characterization of a phiBP endolysin encoded by the *Paenibacillus polymyxa* CCM 7400 phage. FEMS microbiology letters. 2015 Jul 1; 362(13). https://doi.org/10.1093/femsle/fnv098 PMID: 26085488

43. Keiser SC, Swift S, Korobova O, Schischkova N, Kopyliv P, Donovan DM, et al. Lytic activity of the staphylophilic Twort phage endolysin CHAP domain is enhanced by the SH3b cell wall binding domain. FEMS microbiology letters. 2015 Jan 1; 362(1). https://doi.org/10.1093/femsle/fnu019 PMID: 25790497

44. Donovan DM, Foster-Frey J. LambdaSa2 prophage endolysin requires Cpl-7-binding domains and amide-5 domain for antimicrobial lysis of streptococci. FEMS microbiology letters. 2008 Oct; 287(1):22–33. https://doi.org/10.1111/j.1574-6968.2008.01287.x PMID: 18673393

45. Kaplan SL, Barson WJ, Lin PL, Romero-JR, Bradley JS, Tan TQ, et al. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. The Pediatric infectious disease journal. 2013 Mar; 32(3):203–7. https://doi.org/10.1097/INF.0b013e318275614b PMID: 23558320